Narcolepsy Market Insight, Epidemiology, and Market Forecast - 2034: Innovation in Wake-Promoting Therapies and Personalized Approaches | DelveInsight

Narcolepsy, a chronic neurological disorder affecting the brain's ability to regulate sleep-wake cycles, significantly impairs patients' daily functioning and quality of life. Characterized by excessive daytime sleepiness, cataplexy, sleep paralysis, hallucinations, and disrupted nighttime sleep, narcolepsy is categorized into two main types: Type 1 (with cataplexy) and Type 2 (without cataplexy). Although it remains underdiagnosed and frequently misidentified as other sleep or psychiatric disorders, increasing awareness and improved diagnostic tools are helping to identify cases earlier and more accurately.

The narcolepsy treatment landscape is currently dominated by symptomatic therapies, including wake-promoting agents, sodium oxybate, and stimulants. However, the market is evolving, driven by advancements in orexin biology, novel drug delivery systems, and personalized medicine approaches. Several promising therapies targeting the orexin/hypocretin system and other novel pathways are under clinical development, aiming to provide more effective, long-lasting, and safer treatment options.

DelveInsight's report, Narcolepsy - Market Insight, Epidemiology, and Market Forecast - 2034, offers a comprehensive analysis of the global narcolepsy market, covering epidemiological trends, patient segmentation by type, age, and gender, and treatment paradigms across major markets including the United States, EU4 (Germany, France, Italy, Spain) and the UK, and Japan. The report also highlights current unmet needs, market drivers, and barriers, and emerging therapies that are poised to reshape the therapeutic landscape.

With growing recognition of narcolepsy as a serious and chronic condition, combined with the rise of innovative treatment modalities and increased research into the neurobiology of sleep disorders, the narcolepsy market is expected to witness steady growth and enhanced patient outcomes by 2034.

Request a sample and uncover the latest breakthroughs shaping the Narcolepsy market landscape and future outlook @ https://www.delveinsight.com/report-store/narcolepsy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Some of the key insights of the Narcolepsy Market Report:
• The narcolepsy market is expected to grow significantly through the forecast period (2024-2034).
• According to the Journal of Clinical Sleep Medicine (2022), narcolepsy prevalence in Europe is about 47 cases per 100K people, with an annual incidence of 0.64-1.37 per 100K.
• Kon et al. (2024) report a global prevalence of roughly 1 in 2K, with Japan having a higher rate of approximately 1 in 600; the average age of onset in Japan is 18 years.
• In 2023, Germany had the lowest narcolepsy prevalence among EU4 countries and the UK, while narcolepsy remains a rare disease in Spain.
• The highest prevalence for narcolepsy type 1 (NT1) is in those aged 35 or younger, whereas narcolepsy type 2 (NT2) peaks between ages 35 and 54.
• In November 2024, Axsome Therapeutics announced that AXS-12 (reboxetine) met the primary endpoint in the ENCORE Phase III trial for narcolepsy. The drug significantly reduced the frequency of cataplexy attacks compared to placebo and was well tolerated with a consistent safety profile during long-term use. The trial included a 6-month open-label treatment followed by a 3-week randomized withdrawal phase.
• In Oct 2024, Avadel Pharmaceuticals announced that FDA Approval of LUMRYZ Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or EDS in Patients 7 Years of Age and Older with Narcolepsy. In May 2023, the FDA has granted final approval to LUMRYZ for the treatment of cataplexy or EDS in adults with narcolepsy.
• ​In August 2024, Alkermes began the Vibrance-2 Phase II trial to evaluate ALKS 2680, a once-daily oral treatment for narcolepsy type 2 (NT2). The study will assess its safety and effectiveness in about 80 adults, with results focused on improving wakefulness and reducing daytime sleepiness.
• In June 2024, Takeda presented positive results from its Phase IIb trial of TAK-861 in narcolepsy type 1 (NT1) as late-breaking data presentations at SLEEP 2024, the 38th annual meeting of the American Academy of Sleep Medicine and the Sleep Research Society.
• Emerging therapies for narcolepsy include QUILIENCE, SUVN-G3031, mazindol ER, ALKS 2680, Samelisan, TAK-861, ORX750, and others.
• Key companies involved in the treatment of narcolepsy include Alkermes, Avadel Pharmaceuticals, Axsome Therapeutics, Inc., Centessa Pharmaceuticals, Cephalon Inc., ConSynance Therapeutics, Harmony Biosciences, Jazz Pharmaceuticals, KemPharm, NLS Pharmaceutics, Ono Pharma, Otsuka Pharmaceutical, Reset Therapeutics, Sunovion Pharmaceuticals, Suven Life Sciences, Takeda, Vallon Pharmaceuticals, XWPharma, and others.

To know in detail about the narcolepsy market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: https://www.delveinsight.com/report-store/narcolepsy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Narcolepsy Overview
Narcolepsy is a chronic neurological disorder characterized by impaired regulation of sleep and wakefulness. Individuals with narcolepsy often suffer from excessive daytime sleepiness (EDS) and sudden, uncontrollable episodes of sleep at any time during the day. While the exact cause remains unclear, research points to a combination of factors such as autoimmune responses, genetic predisposition, and brain injuries.

Current treatments for narcolepsy primarily focus on managing symptoms based on their severity. Alongside lifestyle modifications, pharmacological options include stimulants, sodium oxybate, histamine H3 receptor antagonists, and antidepressants. Some of the approved medications in the market are WAKIX (pitolisant) by Harmony Biosciences, XYREM (sodium oxybate) by Jazz Pharmaceuticals, and SUNOSI (solriamfetol) developed by Axsome Therapeutics in partnership with Jazz Pharmaceuticals.

Get a free sample for the narcolepsy market forecast, size & share analysis report: https://www.delveinsight.com/report-store/narcolepsy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Narcolepsy Epidemiology
The epidemiology section offers an overview of historical, current, and projected trends in the seven major countries (7MM) from 2020 to 2034. It helps identify the factors influencing these trends by examining various studies and perspectives from key opinion leaders. Additionally, the section provides an in-depth analysis of the diagnosed patient population and future trends.

Narcolepsy Epidemiology Segmentation:
The Narcolepsy market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM, segmented into:
• Total Diagnosed Prevalent Cases of Narcolepsy
• Subtype-Specific Diagnosed Prevalent Cases of Narcolepsy
• Age-Specific Diagnosed Prevalent Cases of Narcolepsy
• Treated Cases of Narcolepsy

Narcolepsy Drugs Uptake and Pipeline Development Activities
The Drug Uptake section offers a detailed analysis of the adoption trends of newly launched and upcoming therapies for Narcolepsy throughout the study period. It evaluates patient adoption rates, market penetration, and the commercial performance of each therapy, providing a clear understanding of the factors driving or hindering the market acceptance of these treatments.

The Therapeutics Assessment further highlights the Narcolepsy drugs, demonstrating the most rapid uptake. It examines the underlying drivers contributing to their swift adoption and compares the market share of these therapies to identify those gaining significant traction.

Additionally, the report provides an in-depth overview of the current therapeutic pipeline for Narcolepsy, covering investigational drugs at various stages of development. It profiles the key pharmaceutical and biotech companies actively involved in advancing targeted treatments and presents the latest updates on partnerships, mergers and acquisitions, licensing deals, and other strategic developments shaping the future of Narcolepsy therapeutics.

Explore how emerging narcolepsy therapies are aligning with evolving patient populations @ https://www.delveinsight.com/report-store/narcolepsy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Narcolepsy Market Outlook
The Narcolepsy therapeutics market is expected to see significant growth between 2024 and 2034, driven by rising disease prevalence, improved diagnostics, and greater awareness. Current treatments mainly focus on symptom management, including stimulants, sodium oxybate, histamine H3 receptor antagonists, and antidepressants. However, a growing pipeline of novel therapies and recent regulatory incentives, such as orphan drug designations for Abliva's NV354 and Vatiquinone, highlight increasing investment in targeted treatments.

Key approved therapies include Jazz Pharmaceuticals' XYREM (sodium oxybate) for cataplexy and excessive daytime sleepiness (EDS), Harmony Biosciences' WAKIX (pitolisant), which is not a controlled substance, and Axsome Therapeutics' SUNOSI, a dopamine and norepinephrine reuptake inhibitor. In 2024, Avadel Pharmaceuticals received FDA approval for LUMRYZ, an extended-release sodium oxybate formulation for patients aged seven and older.

Ongoing clinical trials and advancements in gene therapy and metabolic modulators are expected to reshape the market landscape, offering potential disease-modifying treatments. According to DelveInsight, these innovations and unmet needs will drive considerable market evolution across the seven major markets (7MM) from 2020 to 2034.

Narcolepsy Market Drivers
• Growing recognition of narcolepsy, along with improved diagnostic methods, is expanding the diagnosed patient pool, thereby boosting demand for effective therapies.
• The development of novel therapies, including new drug formulations and mechanisms of action like histamine receptor antagonists and reuptake inhibitors, is driving market growth and offering improved symptom management.

Narcolepsy Market Barriers
• Current therapies primarily manage symptoms without curing the disease, which limits long-term patient outcomes and market expansion potential.
• The expensive nature of some narcolepsy medications and limited access in certain regions pose challenges to widespread adoption and treatment adherence.

Scope of the Narcolepsy Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan].
• Key Narcolepsy Companies: Alkermes, Avadel Pharmaceuticals, Axsome Therapeutics, Inc., Centessa Pharmaceuticals, Cephalon Inc., ConSynance Therapeutics, Harmony Biosciences, Jazz Pharmaceuticals, KemPharm, NLS Pharmaceutics, Ono Pharma, Otsuka Pharmaceutical, Reset Therapeutics, Sunovion Pharmaceuticals, Suven Life Sciences, Takeda, Vallon Pharmaceuticals, XWPharma, and others.
• Key Narcolepsy Therapies: QUILIENCE, SUVN-G3031, mazindol ER, ALKS 2680, Samelisan, TAK-861, ORX750, and others.
• Narcolepsy Therapeutic Assessment: Narcolepsy currently marketed, and Narcolepsy emerging therapies.
• Narcolepsy Market Dynamics: Narcolepsy market drivers and Narcolepsy market barriers.
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies.
• Narcolepsy Unmet Needs, KOL's views, Analyst's views, Narcolepsy Market Access and Reimbursement.

To learn more about narcolepsy companies working in the treatment market, visit @ https://www.delveinsight.com/report-store/narcolepsy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Narcolepsy Market Report Introduction
2. Executive Summary for Narcolepsy
3. SWOT analysis of Narcolepsy
4. Narcolepsy Patient Share (%) Overview at a Glance
5. Narcolepsy Market Overview at a Glance
6. Narcolepsy Disease Background and Overview
7. Narcolepsy Epidemiology and Patient Population
8. Country-Specific Patient Population of Narcolepsy
9. Narcolepsy Current Treatment and Medical Practices
10. Narcolepsy Unmet Needs
11. Narcolepsy Emerging Therapies
12. Narcolepsy Market Outlook
13. Country-Wise Narcolepsy Market Analysis (2020-2034)
14. Narcolepsy Market Access and Reimbursement of Therapies
15. Narcolepsy Market Drivers
16. Narcolepsy Market Barriers
17. Narcolepsy Appendix
18. Narcolepsy Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.